Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Thomas Kaye, RPh, MBA, FASHP
Authored Items
The NCCN Compendium for Cancer Management
Thomas Kaye, RPh, MBA, FASHP
June 2008, Vol 1, No 5
in
Practice Management
Wayward Prescriptions: Costs of Fraud in Payor Plans
Thomas Kaye, RPh, MBA, FASHP
,
Susan Sarnoff, DSW
July/August 2008, Vol 1, No 6
in
Practice Management
Are You Kidding Me? Clinical Comparative Effectiveness or Evidence-Based Medicine
Thomas Kaye, RPh, MBA, FASHP
April/May 2009, Vol 2, No 3
in
Perspectives
Last modified: September 6, 2013
